Contribute Try STAT+ Today

The coronavirus pandemic has presented an extreme challenge for cancer clinical trials, with many shutting down completely in the spring and others struggling to recruit patients too afraid of Covid-19 to risk entering hospitals or clinics. But researchers say there’s been an unexpected silver lining: The many innovations they rapidly ushered into place to make it safer and easier to access clinical trials are working so well for both patients and researchers, they may stay in place long after the epidemic ends.

“People are talking about how the future has been accelerated by this pandemic. Cancer research has been accelerated as well,” said Joe Unger, a health services researcher and biostatistician with the Fred Hutchinson Cancer Research Center in Seattle who tracked how clinical trial enrollment fell off this spring as the pandemic surged. “People and institutions are adapting in such innovative ways. It’s really inspiring.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.